Sapient Capital LLC Lowers Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

Sapient Capital LLC reduced its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 57.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,358 shares of the company’s stock after selling 4,546 shares during the quarter. Sapient Capital LLC’s holdings in TransMedics Group were worth $209,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Hager Investment Management Services LLC bought a new stake in TransMedics Group during the 4th quarter valued at approximately $33,000. Sachetta LLC bought a new position in shares of TransMedics Group during the fourth quarter worth $40,000. Quarry LP boosted its position in shares of TransMedics Group by 557.1% during the third quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after acquiring an additional 312 shares during the last quarter. National Bank of Canada FI grew its stake in TransMedics Group by 174.7% during the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after acquiring an additional 262 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its stake in TransMedics Group by 187.0% during the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after acquiring an additional 316 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Price Performance

TransMedics Group stock opened at $69.52 on Thursday. The firm has a market capitalization of $2.33 billion, a PE ratio of 73.96 and a beta of 2.12. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37. The firm has a 50-day moving average price of $65.75 and a 200-day moving average price of $107.98. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on TMDX. Piper Sandler cut their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research report on Wednesday, December 11th. Robert W. Baird decreased their price objective on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $75.00 target price (down from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a research report on Wednesday, February 5th. Finally, Canaccord Genuity Group lowered their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $122.70.

Insiders Place Their Bets

In other TransMedics Group news, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total value of $93,657.60. Following the sale, the insider now owns 20,843 shares in the company, valued at $1,800,835.20. This trade represents a 4.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.00% of the stock is owned by insiders.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.